Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial

Abstract Methods to deepen clinical responses to ibrutinib are needed to improve outcomes for patients with chronic lymphocytic leukemia (CLL). This study aimed to determine the safety and efficacy of combining a janus kinase (JAK)‐inhibitor with ibrutinib because JAK‐mediated cytokine‐signals suppo...

Full description

Bibliographic Details
Main Authors: David E. Spaner, Lindsay McCaw, Guizhei Wang, Hubert Tsui, Yonghong Shi
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Cancer Medicine
Subjects:
chemokines
chronic lymphocytic leukemia
ibrutinib
janus kinases
ruxolitinib
thrombopoiesis
Online Access:https://doi.org/10.1002/cam4.2042

Internet

https://doi.org/10.1002/cam4.2042

Similar Items